array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2748)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(97) "Harvest Portfolios Group Inc. Sells 7,046 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)"
["snippet_en"]=>
string(300) "Harvest Portfolios Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,340 shares of the biopharmaceutical company's sto"
["url"]=>
string(144) "https://www.marketbeat.com/instant-alerts/harvest-portfolios-group-inc-sells-7046-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-2024-11-06/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/dccc8212-3a85-4003-bde6-62fcf8c852ab"
["source"]=>
string(14) "marketbeat.com"
["publication_date"]=>
string(10) "2024-11-06"
["categories"]=>
array(7) {
[0]=>
string(12) "Stock Market"
[1]=>
string(10) "Divestment"
[2]=>
string(24) "Stock Research & Ratings"
[3]=>
string(11) "Regulations"
[4]=>
string(18) "General Investment"
[5]=>
string(11) "Acquisition"
[6]=>
string(31) "Financial Update/Profit Warning"
}
}
[1]=>
array(7) {
["title_en"]=>
string(90) "Regeneron Pharmaceuticals Stock: Price Decline After Q3 Report Exaggerated (Piper Sandler)"
["snippet_en"]=>
string(107) "Regeneron Pharmaceuticals Stock: Price Decline After Q3 Report Exaggerated (Piper Sandler) | aktiencheck.de"
["url"]=>
string(122) "https://www.aktiencheck.de/exklusiv/Artikel-Regeneron_Pharmaceuticals_Aktie_Kursrueckgang_Q3_Bericht_uebertrieben-17763808"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/3c2c544c-f9cb-4429-af17-5e404cd29198"
["source"]=>
string(14) "aktiencheck.de"
["publication_date"]=>
string(10) "2024-11-05"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(24) "Stock Research & Ratings"
}
}
[2]=>
array(7) {
["title_en"]=>
string(58) "Regeneron Pharmaceuticals: Price target reduction (Truist)"
["snippet_en"]=>
string(69) "Regeneron Pharmaceuticals: Price target cut (Truist) | aktiencheck.de"
["url"]=>
string(94) "https://www.aktiencheck.de/exklusiv/Artikel-Regeneron_Pharmaceuticals_Kurszielsenkung-17759728"
["image_url"]=>
NULL
["source"]=>
string(14) "aktiencheck.de"
["publication_date"]=>
string(10) "2024-11-05"
["categories"]=>
array(2) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Stock Research & Ratings"
}
}
[3]=>
array(7) {
["title_en"]=>
string(99) "BMO Cuts Regeneron Price Target Following Eylea HD Struggles, Competitive Concerns By Investing.com"
["snippet_en"]=>
string(85) "BMO Cuts Regeneron Price Target Following Eylea HD Struggles and Competition Concerns"
["url"]=>
string(172) "https://fr.investing.com/news/company-news/bmo-reduit-lobjectif-de-cours-de-regeneron-suite-aux-difficultes-deylea-hd-et-aux-inquietudes-liees-a-la-concurrence-93CH-2626510"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2024-11-03"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(11) "Competition"
}
}
[4]=>
array(7) {
["title_en"]=>
string(104) "Regeneron price target lowered following Eylea HD difficulties and competitive concerns By Investing.com"
["snippet_en"]=>
string(98) "Regeneron's price target revised downward following Eylea HD difficulties and competitive concerns"
["url"]=>
string(172) "https://fr.investing.com/news/company-news/lobjectif-de-cours-de-regeneron-revu-a-la-baisse-suite-aux-difficultes-deylea-hd-et-aux-inquietudes-concurrentielles-93CH-2626490"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2024-11-02"
["categories"]=>
array(2) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Stock Research & Ratings"
}
}
[5]=>
array(7) {
["title_en"]=>
string(54) "(3⁺) REGENERON - Can you buy the dip by the numbers?"
["snippet_en"]=>
string(143) "Regeneron stock was one of the big losers in the Nasdaq 100 yesterday. It took third place on the losers list. Are there new opportunities now?"
["url"]=>
string(87) "https://stock3.com/news/regeneron-kann-man-den-einbruch-nach-den-zahlen-kaufen-15646145"
["image_url"]=>
NULL
["source"]=>
string(10) "stock3.com"
["publication_date"]=>
string(10) "2024-11-02"
["categories"]=>
array(2) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Stock Research & Ratings"
}
}
[6]=>
array(7) {
["title_en"]=>
string(101) "Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? - Regeneron Pharmaceuticals (NASDAQ:REGN)"
["snippet_en"]=>
string(165) "Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance."
["url"]=>
string(114) "https://www.benzinga.com/general/biotech/24/10/41660999/why-is-regeneron-pharmaceuticals-stock-trading-lower-today"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ac81cb62-3459-42f2-a014-cd23fa6e0e44"
["source"]=>
string(12) "benzinga.com"
["publication_date"]=>
string(10) "2024-11-01"
["categories"]=>
array(4) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(24) "Stock Research & Ratings"
[3]=>
string(31) "Financial Update/Profit Warning"
}
}
[7]=>
array(7) {
["title_en"]=>
string(52) "Regeneron Stock: [PLACEHOLDER]: Can it really be? ()"
["snippet_en"]=>
string(69) "Regeneron Stock: [PLACEHOLDER]: Can it really be? () | aktiencheck.de"
["url"]=>
string(98) "https://www.aktiencheck.de/news/Artikel-Regeneron_Aktie_PLACEHOLDER_Kann_es_wirklich_sein-17740786"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b010024d-d01d-4cb9-87b5-f26b5dbb340e"
["source"]=>
string(14) "aktiencheck.de"
["publication_date"]=>
string(10) "2024-10-31"
["categories"]=>
array(2) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Stock Research & Ratings"
}
}
[8]=>
array(7) {
["title_en"]=>
string(58) "Piper Sandler Affirms Positive Outlook for Regeneron Stock"
["snippet_en"]=>
string(167) "Piper Sandler maintains a positive outlook on Regeneron, upholding an Overweight rating with a target price of $1,242 amid competitive challenges and growth potential."
["url"]=>
string(96) "https://investorshangout.com/piper-sandler-affirms-positive-outlook-for-regeneron-stock-103904-/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/cd508200-9961-4645-b4fd-863f273f762f"
["source"]=>
string(20) "investorshangout.com"
["publication_date"]=>
string(10) "2024-10-30"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(18) "General Investment"
[2]=>
string(24) "Stock Research & Ratings"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(263)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(201)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(196)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(129)
}
[4]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(116)
}
[5]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(116)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(93)
}
[7]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(79)
}
[8]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(67)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(66)
}
[10]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(61)
}
[11]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(59)
}
[12]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(57)
}
[13]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(56)
}
[14]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(53)
}
[15]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(43)
}
[16]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(40)
}
[17]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(38)
}
[18]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(37)
}
[19]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(37)
}
[20]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(37)
}
[21]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(35)
}
[22]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[23]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(32)
}
[24]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(31)
}
[25]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(28)
}
[26]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(28)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(25)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(21)
}
[29]=>
array(2) {
["name"]=>
string(21) "Intellectual Property"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Website
https://www.regeneron.com
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Articles
2024-11-06 (marketbeat.com)
Harvest Portfolios Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,340 shares of the biopharmaceutical company's sto
Read more
2024-11-05 (aktiencheck.de)
Regeneron Pharmaceuticals Stock: Price Decline After Q3 Report Exaggerated (Piper Sandler) | aktiencheck.de
Read more
2024-11-05 (aktiencheck.de)
Regeneron Pharmaceuticals: Price target cut (Truist) | aktiencheck.de
Read more
2024-11-03 (investing.com)
BMO Cuts Regeneron Price Target Following Eylea HD Struggles and Competition Concerns
Read more
2024-11-02 (investing.com)
Regeneron's price target revised downward following Eylea HD difficulties and competitive concerns
Read more
2024-11-02 (stock3.com)
Regeneron stock was one of the big losers in the Nasdaq 100 yesterday. It took third place on the losers list. Are there new opportunities now?
Read more
2024-11-01 (benzinga.com)
Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.
Read more
![Regeneron Stock: [PLACEHOLDER]: Can it really be? ()](https://images.businessradar.com/articles/b010024d-d01d-4cb9-87b5-f26b5dbb340e)
2024-10-31 (aktiencheck.de)
Regeneron Stock: [PLACEHOLDER]: Can it really be? () | aktiencheck.de
Read more
2024-10-30 (investorshangout.com)
Piper Sandler maintains a positive outlook on Regeneron, upholding an Overweight rating with a target price of $1,242 amid competitive challenges and growth potential.
Read more
